A drug to be really excited about in the future: retatrutide The New England Journal of Medicine just published data on a phase 2 trial of retatrutide, which is a drug that stimulates GLP-1 and GIP (just like tirzepatide) but also stimulates another hormone called glucagon
thus, the reduction in fatty acids in bFLS treated with bTNF- could be attributable to the reduction in the noncanonical TCA cycle via ATP-dependent citrate lyase (ACLY) and acetyl-CoA 43
Remember, it is important to use this medication regularly to get the most benefit from it
Pacifico L, Bonci E, Marandola L, Romaggioli S, Bascetta S, Chiesa C
This is crucial, as oxidative stress can lead to cellular damage and contribute to various chronic diseases
After the first year, annual TSH monitoring is typically sufficient if levels remain stable